Trial Profile
A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Irosustat (Primary) ; Aromatase inhibitors
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms IRIS; IRISv1-0
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 28 Jan 2016 Accrual to date is 100% according to United Kingdom Clinical Research Network record.
- 04 Dec 2013 Accrual to date is 66% according to United Kingdom Clinical Research Network record.